All In Biotech

Drug Trial Radar · NCT00842816

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy, Safety and Tolerability of ST101 Tablets in the Treatment of Alzheimer's Disease in Subjects Concurrently Receiving Donepezil (Aricept®)

Last checked: Nov 19, 2026Latest source record: Jun 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Feb 2009

Primary completion

May 2011

Study completion May 2011

Sponsor

Lead sponsor
Sonexa Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 12, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease who currently receive 10 mg Aricept® (donepezil) per day. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo. All eligible subjects will be provided with bottles of 10 mg Aricept (donepezil) during the study drug administration part of the study.

Conditions

  • Alzheimer's Disease

Interventions

  • ST101Drug

    10 mg; administered once/day

  • ST101Drug

    60 mg; administered once/day

  • ST101Drug

    120 mg; administered once/day

  • PlaceboDrug

    placebo tablets to match ST101 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-cog)Time frame: Baseline, 4 weeks, 8 weeks, 12 weeks

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Costa Mesa, California

  • Site not named

    Redlands, California

  • Site not named

    San Diego, California

  • Site not named

    Walnut Creek, California

  • Site not named

    Hamden, Connecticut

  • Site not named

    Brooksville, Florida

  • Site not named

    Deerfield Beach, Florida

  • Site not named

    Delray Beach, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Decatur, Georgia

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Summit, New Jersey

  • Site not named

    Toms River, New Jersey

  • Site not named

    Durham, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Toledo, Ohio

  • Site not named

    Jenkinton, Pennsylvania

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    East Providence, Rhode Island

  • Site not named

    Houston, Texas

  • Site not named

    Wichita Falls, Texas

  • Site not named

    Bennington, Vermont

  • Site not named

    Kirkland, Washington

  • Site not named

    Peterborough, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.